Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Beyondspring Inc (BYSI)

Beyondspring Inc (BYSI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 77,437
  • Shares Outstanding, K 40,332
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,120 K
  • EBIT $ -9 M
  • EBITDA $ -8 M
  • 60-Month Beta 0.53
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 316.93% (-68.61%)
  • Historical Volatility 113.39%
  • IV Percentile 85%
  • IV Rank 46.67%
  • IV High 646.81% on 04/10/25
  • IV Low 28.25% on 11/20/25
  • Expected Move (DTE 21) 0.4675 (25.41%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 46
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 6,218
  • Open Int (30-Day) 6,142
  • Expected Range 1.3725 to 2.3075

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7050 +7.92%
on 12/19/25
2.4400 -24.59%
on 12/12/25
-0.2500 (-11.96%)
since 11/26/25
3-Month
1.6000 +15.00%
on 10/15/25
2.4400 -24.59%
on 12/12/25
+0.0800 (+4.55%)
since 09/26/25
52-Week
0.9800 +87.76%
on 04/07/25
3.4400 -46.51%
on 06/17/25
+0.1793 (+10.80%)
since 12/26/24

Most Recent Stories

More News
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path

Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement in...

BYSI : 1.8400 (-4.17%)
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025

In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin...

BYSI : 1.8400 (-4.17%)
BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update

Two SITC 2025 presentations: First-in-class dendritic cell (DC) maturation agent Plinabulin drives immune re-sensitization in metastatic NSCLC patients who had progressed after PD-1/L1 inhibitors with...

BYSI : 1.8400 (-4.17%)
BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment

ASCO 2025 presentation: First-in-class agent Plinabulin drives immune re-sensitization in NSCLC patients progressed to PD-1/L1 therapies Med  (Cell Press) Publication with MD Anderson Collaboration...

BYSI : 1.8400 (-4.17%)
BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure

BYSI : 1.8400 (-4.17%)
Big Cuts to U.S. Cancer Research May Create Historic Opening for Biotech Investors

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The future of cancer research appears to be drifting away from the public sector to the private sector,...

ONCY : 0.9520 (-1.86%)
BYSI : 1.8400 (-4.17%)
ELEV : 0.3650 (-2.12%)
ONC.TO : 1.42 (+2.16%)
OSTX : 1.5100 (-0.66%)
CRDF : 3.17 (-0.31%)
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting

BYSI : 1.8400 (-4.17%)
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting

BYSI : 1.8400 (-4.17%)
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update

BYSI : 1.8400 (-4.17%)
BeyondSpring Files 2024 Annual Report on Form 10-K

BYSI : 1.8400 (-4.17%)

Business Summary

BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company's lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced...

See More

Key Turning Points

3rd Resistance Point 2.0385
2nd Resistance Point 1.9793
1st Resistance Point 1.9496
Last Price 1.8400
1st Support Level 1.8607
2nd Support Level 1.8015
3rd Support Level 1.7718

See More

52-Week High 3.4400
Fibonacci 61.8% 2.5003
Fibonacci 50% 2.2100
Fibonacci 38.2% 1.9197
Last Price 1.8400
52-Week Low 0.9800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar